Eukaryotic protein synthesis is a highly coordinated process involving the interaction of a large number of factors that participate in the assembly of ribosomes and aminoacylated tRNAs onto mRNA templates, followed by their correct and efficient translation into proteins. Regulation of protein synthesis is mainly achieved at the initiation step, and occurs through modulation of translation factor levels or activity. 1 Small molecule ligands that inhibit the process of translation have provided exquisite insight into ribosome function and translation factor activity in both prokaryotes and eukaryotes. [2] [3] [4] In addition, a growing number of studies indicate that deregulation of protein synthesis is a major contributor to carcinogenesis and subsequent metastasis. 5 For instance, overexpression of certain initiation factors has been associated with malignant transformation, whereas suppression of these same factors can restrict the transformed carcinogenic phenotype. Additionally, components of the translational machinery not solely associated with initiation are often overexpressed or mutated in cancers. Thus, the identification of small molecules able to modulate translational processes represents an endeavor, important not only in understanding the mechanics of translation but also in the development of new therapeutic candidates that exploit the unique translational features characteristic of cancer cells.
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We previously reported the use of a high-throughput bicistronic mRNA translation screen to identify inhibitors of eukaryotic protein synthesis. 6, 7 The application of this translation screen leads to the discovery of several new modulators of translation initation. 8, 9 We now report here the application of this translation inhibition screen to identify natural product inhibitors of translation produced by two new endophytic actinomycetes.
During the course of our efforts to identify novel natural products from microorganisms from diverse and unique ecological niches, [10] [11] [12] [13] we isolated a collection of actinomycete strains from endophytes and soil samples originating from the Yunnan province of China. Subjection of crude extract libraries of this collection to translation inhibition assay indicated the presence of potential translation inhibitors in two of the crude extracts prepared from the endophytic actinomycete Streptomyces sps. YIM56132 from Carex baccaus and YIM56141 from Fagopyrum cumosum; both plants were isolated from the Xishuangbanna Perfecture of Yunnan, where they are widely used to treat arthritis. Both extracts also possessed components possessing moderate cytotoxic activity against selected human cancer cells and having similar HPLC profiles. Subsequent large-scale fermentation (6 l) and bioassay-guided fractionation with extracts from both YIM56132 and YIM56141 yielded two fractions whose components inhibited translation. Thorough evaluation of each extract revealed the presence of cycloheximide (1), 14 iso-cycloheximide (2), 14 A-75943 (3), 15 two new cycloheximide congeners-secocycloheximides A (4) and B (5), as well as actiphenol (6), 16 AH-135Y (7) 16 and phenatic acid A (8) 16 in the YIM56141 extract, whereas 1, 2 and 4-8 were also found in the YIM56132 extract (Figure 1a ). In addition, four previously known diketopiperazines 11-14 were also found in the YIM56141 extract (Supplementary Information). Dereplication revealed 3 and 4 to be new congeners of 1, and concomitant efforts revealed that 1 and 2 were mainly responsible for translation inhibition and cytotoxicity. We also found that 3 showed selective cytotoxicity against breast cancer cell lines and that 6 was a weak translation inhibitor. All other compounds were devoid of activity (Table 2 ). Both 6 and 7 were subjected to selective reduction by NaBH 4 to afford the corresponding 8-hydroxy analogs 9 and 10 ( Figure 1a and Supplementary Information). Interestingly, 9 is a significantly more potent inhibitor of translation than 6 ( Table 2 ). This finding hints at the importance of C-8 oxidation state in determining the extent to which these natural products inhibit eukaryotic translation.
Efforts to elucidate natural product structures from YIM56141 and YIM56132 relied heavily on HR-MS and NMR spectroscopy analyses and were facilitated by prior knowledge of 1. APCI-MS analysis of 1-3 afforded the same protonated [M+H] + ion at m/z 282 and suggested a molecular formula of C 15 H 23 NO 4 . Combined with the 1 H and 13 C NMR and HR-MS data suggested that 1-3 are cycloheximide, 14 iso-cycloheximide 14 and A-75943 (see Morishita et al. 15 ), respectively. The 1 H and 13 C NMR spectra of purified 1-3 were assigned on the basis of extensive 1D and 2D NMR (gCOSY, gHSQC and gHMBC) and HR-ESI-MS analyses, and comparison with the spectroscopic data previously reported (Table 1) . Through careful analysis of the MS, HMBC and COSY spectra, the structure was deduced to be secoanhydrocycloheximide 14 as shown in Figure 1b (Figure 1b) . The relative stereochemistry of C-11 and C-13 in 4 was established by analyzing information from the ROESY spectrum (Supplementary Information) and by comparison of its spectroscopic data with those of 1 and anhydrocycloheximide. 14 The relative configuration at C-4 in 4 cannot be determined from spectroscopic data alone. Fortunately, we found that 4 was converted into 3 during silica gel chromatography using a chloroform-methanol gradient (from 100:1 to 4:1). This observation is easily rationalized by intramolecular Michael addition in a highly favored 6-exo-trig fashion (Supplementary Information). Given this rationale and the non-labile nature of C-4 in both 3 and 4, we reasoned that 3 and 4 share the same stereochemical configuration. Consequently, ROESY and coupling constant data were used to establish the relative stereochemistry of 3. The configurations for C-11 and C-13 are supported by strong ROESY correlations of H-11 (d H 2.45) and H-9 (d H 2.84), with H 3 -16 (d H 0.94) as shown in molecular models (Figure 1c) Figure 1c . These relative stereochemistry assignments are identical to those previously reported. 15 Consequently, the complete structure of 3, hence the same stereochemistry at C-4 for 4, was deduced as shown in Figure 1a . Secocycloheximide B (5) was assigned the same molecular formula, C 15 H 23 NO 4 , as that of 4, on the basis of its HR-ESI-MS and 1 H and 13 C NMR data. Careful 1D and 2D NMR analyses showed that 5 has the same cyclohexanone scaffold as 4. However, the dramatically different chemical shifts of C-11, C-12 and C-13 in the 13 C NMR for 4 and 5 (Table 1) supports the notion that an epimerized C-11 differentiates 5 from other cyclohexanone-containing metabolites produced by cycloheximide producers. 19 In addition, the stereochemistry of C-4 was tentatively assigned to be the same as that of 4 on the basis of shared biosynthetic machineries.
All compounds isolated were evaluated for their ability to inhibit eukaryotic translation in Krebs-2 extracts programmed with capped-(CAG) 33 FF/HCV/RenpA 51 mRNA as described previously; 7 from these efforts was derived a clear correlation of structure to activity (Table 2A) . Both 1 and 9 inhibited translation from the firefly and renilla luciferase cistrons in a dose-dependent manner, whereas 6 showed only weak inhibitory activity. Interestingly, 9 is a significantly more potent translation inhibitor than its 8-oxo-variant 6 (Table 2B) . This finding supports earlier work highlighting the importance of glutarimide side chain hydroxylation in endowing the glutarimidecontaining polyketides, such as 1 and lactimidomycin, with biological activities surpassing those of non-hydroxylated congeners. 20, 21 All compounds isolated were also tested for cytotoxicity against human breast cancer MDA-MB-231, human prostate carcinoma Du145, human colon cancer HCT-15 and human breast adenocarcinoma MCF7 cell lines using previously described methods (Table 2B) . 22 Both 1 and 2 demonstrated comparable inhibitory activity against all the cell lines, suggesting the relative unimportance of C-11 stereochemistry, whereas 3 demonstrated activity only against breast cancer cell lines MDA-MB-231 and MCF7. The IC 50 s for 3 were B10-fold higher than demonstrated for 1 and 2, suggesting that loss of the glutarimide, presence of the lactone moiety, or both, relative to 1 and 2, detrimentally impacts cytotoxic activity. All other compounds were found to be inactive against all the four cancer cell lines (no detectable cytotoxicity at 10 mM).
In summary, we have found two new endophytic cycloheximide producers Streptomyces sps. YIM56132 and YIM56141 from unique ecological niches using a novel bicistronic mRNA translation assay and have isolated two new cycloheximide congeners 4 and 5, which contain carboxylic acid and primary amide functionalities instead of an intact glutarimide. Most importantly, translation inhibition assays showed that the presence of a hydroxyl group at C-8 significantly improves inhibitory activity. This discovery could, therefore serve as a scaffold for the chemical synthesis and biosynthesis of more potent modified eukaryotic protein synthesis inhibitors. The structural differences of 1 and 6 is that the latter replaces the cyclohexanone moiety of 1 with a substituted phenol and the C-8 hydroxyl moiety with a ketone at C-8. Thus, the dual production of both 1 and 6 in the same strain is biosynthetically intriguing, as both polyketides must be derived from the same biosynthetic machinery. It is, therefore not clear which compound precedes the other during biosynthesis, and which one may represent a shunt metabolite. Perhaps the most interesting insight into biosynthesis of glutarimidecontaining antibiotics by Streptomyces sps. YIM56132 and YIM56141 is gleaned by the isolation of glutarimide ring opened-natural products 4, 5 and 8 from the wild-type strains. Isolation of these compounds raises the possibility that glutarimide installation might be catalyzed by a post-PKS enzyme encoded by the corresponding gene cluster. In light of the significant and novel bioactivities of glutarimide-containing polyketides such as 1, lactimidomycin, migrastatin and iso-migrastatin, the questions raised here clearly warrant further attention, perhaps best addressed in continued studies of 1 and 6 biosynthesis in Streptomyces sps YIM56132 and YIM56141.
